Brief: Kolon Tissuegene Highlights Long-Term Safety Data And Potential U.S. FDA Pathway For Tg-C At Oarsi World Congress
28/04/2025 14:53
April 28 (Reuters) - Kolon TissueGene Inc 950160.KQ: KOLON TISSUEGENE HIGHLIGHTS LONG-TERM SAFETY DATA AND POTENTIAL U.S. FDA PATHWAY FOR TG-C AT OARSI WORLD CONGRESS Source text: ID:nPregWcQQa Further company coverage: 950160.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kolon TissueGene
See all newsBrief: Kolon Tissuegene To Conduct Capital Increase Of 60 Billion Won For Operational Funds
Brief: Kolon Tissuegene Highlights Long-Term Safety Data And Potential U.S. FDA Pathway For Tg-C At Oarsi World Congress
Brief: Kolon Tissuegene To Conduct Capital Increase Of 44 Billion Won For Operational Funds
Brief: Kolon Tissuegene To Conduct Capital Increase Of 48 Billion Won For Operational Funds
Brief: Kolon Corp 2017/2018 Financial Statements Are Subject To Change Depending On Audit Results